ESTRO 2021 Abstract Book

S1183

ESTRO 2021

Conclusion LPBI with HT is a promising new high conformal technique very effective in the treatment of widespread metastatic bone disease and with excellent tolerance rates.

PO-1442 Fractionated stereotactic radiotherapy (SRS) for brain metastases: a single institution analysis. L. Garnier 1,2 , L. Lestrade 1,3 , A. Falcoz 4,5 , J. Henriques 4,5 , F. Boulbair 6 , J. Rouvier 6 , D. Vernerey 4,5 , Y. Hammoud 6 , B. De Bari 7,1 1 University Hospital of Besançon, Radiation Oncology, Besançon, France; 2 Pierre Wertheimer Hospital, Medical Oncology, Lyon, France; 3 Swiss Medical Network, Radiation Oncology, Génolier, Switzerland; 4 University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit, Besançon, France; 5 Bourgogne Franche-Comté University, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France; 6 Nord Franche Comté Hospital, Radiation Oncology, Montbéliard, France; 7 Neuchâtel Hospital Network, Radiation Oncology, La Chaux-de-Fonds, Switzerland Purpose or Objective Brain Metastases (BMs) are the most common intracranial neoplasm in adult and occur in approximately 20–40% of pts with systemic cancer. The new era of treatment, especially with targeted therapy and immunotherapy, allows cancer pts to have extended survival, so that focal treatments as SRS could be more aggressive and, potentially, more ambitious. We retrospectively reviewed the clinical outcomes of pts traited with SRS in our institution for BMs. Materials and Methods We included all pts consecutively treated with SRS with or without Whole Brain Radiotherapy (WBRT) for BMs in our Institution. Postoperative SRS was an exclusion criterium. The primary endpoint of the study was the assessment of local and intracranial control. Secondary endpoints were overall survival and the analysis of toxicity rates, in particular radionecrosis. Results A total of 261 BMs were retrospectively investigated in 104 pts. One hundred and seventy-eight (68%) lesions were treated with SRS alone. Median age was 67 years (range: 48 - 87). KPS was >90 in 48 pts and <90 in 56 pts and Thirty-five (33%) patients received also a WBRT, 13/35 before and 22/35 after SRS, with a median time of 12 [range 1-72] and 4.5 [range 1-18] months between these two regimens, respectively. The median PTV size was 8.26 cm3 (range: 0.5 - 44).